Introgen Therapeutics, Inc. to Present at Canaccord Adams' 27th Global Growth Conference

Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that it will deliver a presentation at the 27th Annual Canaccord Adams Global Growth Conference in Boston. David G. Nance, president and CEO, is scheduled to present to leading institutional investment representatives on Thursday, August 9, 2007, at 11:00 a.m. ET, at the InterContinental Boston. Mr. Nance’s presentation will be webcast live and will be available at www.introgen.com. About Introgen Therapeutics Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of targeted tumor suppressors, a new class of therapies for the treatment of cancer. Introgen’s technology delivers targeted molecular therapies that increase production of normal cancer-fighting proteins and cytokines. The Company is developing a proprietary pipeline of product candidates utilizing molecular biomarkers to identify patients most likely to benefit from its therapies which target central cancer-causing mechanisms. ADVEXIN®, its lead product candidate, targets abnormal p53, a fundamental cancer defect present in over 50 percent of all tumors. Introgen is analyzing its phase 3 clinical trial for recurrent head and neck cancer using ADVEXIN as a monotherapy. The Company plans to complete regulatory filings in both the United States and in Europe by the end of 2007. For more information about the Company, please visit www.introgen.com.